Charles Schwab Investment Management Inc. Acquires 41,374 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Charles Schwab Investment Management Inc. boosted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,083,302 shares of the company's stock after purchasing an additional 41,374 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.19% of Myriad Genetics worth $29,672,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Myriad Genetics by 34.1% during the third quarter. GAMMA Investing LLC now owns 1,620 shares of the company's stock worth $44,000 after buying an additional 412 shares in the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Myriad Genetics by 75.3% during the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company's stock worth $28,000 after buying an additional 491 shares in the last quarter. Atria Investments Inc lifted its holdings in shares of Myriad Genetics by 5.4% during the third quarter. Atria Investments Inc now owns 11,414 shares of the company's stock worth $313,000 after buying an additional 581 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock worth $87,000 after buying an additional 583 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Myriad Genetics by 3.4% during the second quarter. Arizona State Retirement System now owns 25,160 shares of the company's stock worth $615,000 after buying an additional 829 shares in the last quarter. Institutional investors and hedge funds own 99.02% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on MYGN. Morgan Stanley dropped their price target on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating for the company in a research note on Monday, November 18th. JPMorgan Chase & Co. boosted their price target on Myriad Genetics from $17.00 to $20.00 and gave the company an "underweight" rating in a research note on Wednesday, August 7th. StockNews.com downgraded Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Scotiabank boosted their price target on Myriad Genetics from $29.00 to $34.00 and gave the company a "sector outperform" rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company began coverage on Myriad Genetics in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $35.00 price target for the company. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $27.36.

Myriad Genetics Price Performance

Myriad Genetics stock traded down $0.24 during midday trading on Thursday, reaching $16.36. The company's stock had a trading volume of 541,700 shares, compared to its average volume of 742,059. The stock has a market cap of $1.49 billion, a PE ratio of -12.77 and a beta of 1.87. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $20.46 and a 200-day moving average price of $24.00. Myriad Genetics, Inc. has a 52 week low of $14.72 and a 52 week high of $29.30.

Insider Transactions at Myriad Genetics

In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $27.05, for a total transaction of $270,500.00. Following the completion of the sale, the director now owns 121,648 shares of the company's stock, valued at approximately $3,290,578.40. This represents a 7.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares of the company's stock, valued at $22,067,327.54. This represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.